Navigation Links
Teewinot Life Sciences Corporation Announces Breakthrough Commercial Production of the Cannabinoid Varin Series
Date:2/14/2017

TAMPA, Fla., Feb. 14, 2017 /PRNewswire/ -- Teewinot Life Sciences Corporation (Teewinot), a global leader in the use of biosynthetic processes for the production of kilogram quantities of pharmaceutical grade cannabinoids, announced today that its wholly owned subsidiary, Full Spectrum Laboratories, Ltd. (FSL), can produce commercial quantities of THCVA, CBDVA, CBCVA, and CBGVA (varin series) using its proprietary CannSynthesis™ technology.  Teewinot and FSL are recognized as pioneers in synthesizing pharmaceutically important cannabinoids.  It is not practical to commercially produce the varin series compounds by means of plant extraction because the Cannabis plant only produces small quantities of these cannabinoids.  FSL has developed patent-protected biosynthetic processes for the manufacture of THCVA, CBDVA, CBCDA, and CBGVA using enzymes such as THCA synthase and CBDA synthase.

Dr. Richard Peet, Executive Vice President of Teewinot and co-inventor of the CannSynthesis™ technology stated, "Our proprietary CannSynthesis™ process makes possible the cost-effective production of commercial quantities of pharmaceutically pure cannabinoids that are produced in relatively small quantities by the Cannabis plant.  Using FSL's revolutionary biosynthetic process, it is now possible to envision treating patients with cannabinoids that are impractical to cost-effectively produce in commercial quantities by plant extraction or chemical synthesis."

Jeffrey M. Korentur, Teewinot President and CEO says, "It's hard to overstate the significance that this expansion of our manufacturing catalog provides.  Researchers around the world are demanding better access to this important, and demonstrably effective sub-set of cannabinoids, and Teewinot is excited to be the market leader in this space.  Until now, there has been no commercially reliable method of producing these molecules.  The CannSynthesis™ process ensures global availability of the varin series at a reasonable cost, and with a supply chain that can effortlessly scale to meet the demands of the market.  CannSynthesis™ eliminates the risks associated with agricultural and chemical production methods, yet provides the purest cannabinoids to the research, medical and pharmaceutical communities."

Teewinot is the global leader for commercial production of pharmaceutically pure (>99%) THCA, CBDA, CBCA, CBGA, THCVA, CBDVA, CBCVA, and CBGVA.  Teewinot seeks partners interested in working to commercialize these important cannabinoids and provide patients with new healthcare solutions.

About Teewinot Life Sciences Corporation

Teewinot Life Sciences Corporation is an international biopharmaceutical company focused on advanced pharmaceutical research and the use of novel biosynthetic processes such as biocatalysis and synthetic biology for cannabinoid manufacture.  Coupled with patented formulation technologies, Teewinot is a leader in the production and delivery of cannabinoid-based therapies.  With headquarters in Tampa, Florida, and wholly owned subsidiaries Full Spectrum Laboratories, Ltd, in Ireland, and Canadian Medical Hemp Biotechnologies in Canada, Teewinot's global proprietary technology and intellectual property portfolio represent a breakthrough in the manufacture and delivery of cannabinoid-based pharmaceuticals.  For more information, please visit www.tlscorp.com or follow us on Twitter (@teewinot_corp).

For More Information:

Teewinot Life Sciences Corporation
Drew White
drew@nisonco.com
(631) 520-1435

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/teewinot-life-sciences-corporation-announces-breakthrough-commercial-production-of-the-cannabinoid-varin-series-300406556.html


'/>"/>
SOURCE Teewinot Life Sciences Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Teewinot Life Sciences Corporation Licenses Biosynthetic Technology to AMRI for the Production and Sale of the First Commercially Available CBCA Analytical Standard
2. CSO of Vortex Biosciences Dr. Elodie Sollier-Christen Awarded With 2017 SLAS Innovation Award
3. Swift Biosciences Expands Team, Hires Vice President of Marketing
4. Life Sciences Forum Executives Announced
5. Knowledgent Clinical Cloud Built on Amazon Web Services Transforms Clinical Informatics in Life Sciences
6. Exact Sciences to participate in Leerink Partners Global Healthcare Conference
7. ACEA Biosciences Announces Winners of its Travel Award
8. NSF International’s Bob Pietrowski to Retire as Vice President of Global Health Sciences Division
9. Student-Run DuPont Plant Sciences Symposium Series Kicks Off at University of Missouri
10. AxioMed Continues International Growth with Workshop and Presentation at Caribbean Neurosciences Symposium in Montego Bay
11. WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/30/2019)... ... January 30, 2019 , ... Through its Microbiome ... support in study design, planning, sample collection, and analysis to a team of ... PhD, to study the interactions between gut microbial composition and cardiovascular health risks, ...
(Date:1/24/2019)... , ... January 22, 2019 , ... ... each trial has its own set of assumptions, and RFP creation and management ... evaluating bids is like comparing apples to oranges. These challenges can ultimately lead ...
(Date:1/20/2019)... ... 2019 , ... The American Society of Gene & Cell Therapy (ASGCT) is ... new initiative for 2019. Designed by ASGCT committee volunteers in coordination with patient advocacy ... the public on the status and promise of gene and cell therapies. , ...
(Date:1/11/2019)... ... January 11, 2019 , ... Boekel Scientific ... collection of donor blood. This advanced and intuitive medical device was designed ... the functionality needed for the busiest donor stations with new-to-the industry features to ...
Breaking Biology Technology:
(Date:2/6/2019)... ... February 04, 2019 , ... uBiome, the leader microbial genomics, ... help individuals understand how the gut microbes may increase the risk of arterial ... foods that contain choline and L-carnitine, such as red meat and eggs, various ...
(Date:2/2/2019)... SAN FRANCISCO (PRWEB) , ... January 31, 2019 ... ... the leader in microbial genomics, has awarded microbiome research support in study design, ... Barry Behr, PhD, HCLD, Professor of Obstetrics and Gynecology, and Dr. Sara Vaughn, ...
(Date:1/30/2019)... ... January 30, 2019 , ... ... high-impact life science and biotechnology companies, announced today that it will host ... disease-focused venture funds to discuss their investment philosophies, explain their fund and ...
Breaking Biology News(10 mins):